Bortezomib for multiple myeloma

Author： Popat Rakesh Joel Simon Oakervee Heather Cavenagh Jamie

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.7, Iss.10, 2006-07, pp. : 1337-1346

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bortezomib in multiple myeloma

By Terpos Evangelos Roussou Maria Dimopoulos Meletios-Athanassios

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 5, 2008-05 ,pp. : 639-654

Informa Healthcare

Access to resources Recommend Favorite

An expanding VISTA for bortezomib in multiple myeloma

Inpharma, Vol. 1, Iss. 1645, 2008-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

A review of the proteasome inhibitor bortezomib in multiple myeloma

By Richardson Paul G

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 6, 2004-06 ,pp. : 1321-1331

Informa Healthcare

Access to resources Recommend Favorite

Bortezomib battles the front line in multiple myeloma

Inpharma, Vol. 1, Iss. 1477, 2005-01 ,pp. : 17-18

Adis International

Access to resources Recommend Favorite

Bortezomib: A Review of its Use in Patients with Multiple Myeloma

By Curran Monique P. McKeage Kate

Drugs, Vol. 69, Iss. 7, 2009-05 ,pp. : 859-888

Adis International

Access to resources Recommend Favorite